Skip to main content

2019

November 22, 2019
Background: SAGE-217 is a novel, positive allosteric modulator of GABA(A) receptors under development in Major Depressive Disorder (MDD). This analysis quantified the number needed to treat (NNT) and…
November 22, 2019
Introduction: Esketamine nasal spray for management of treatment-resistant depression (TRD) was assessed using the metrics of number needed to treat (NNT), number needed to harm (NNH), and likelihood…
November 22, 2019
Introduction: Evaluation of patients with serious mental illness (SMI) relies largely on patient or caregiver self-reported disease symptoms. New technologies (e.g., mobile-based interventions,…
November 22, 2019
OBJECTIVE: A substantial segment of the clinical population is Spanish speaking and to serve their needs, this study is to test the validity of the English to Spanish translation of this wellness…
November 22, 2019
Objective: To assess the impact of tAccess patient support program (PSP) on adherence and persistence among adult patients with major depressive disorder (MDD). tAccess PSP, a free program initiated…
November 22, 2019
Involuntary outpatient commitment (OPC) is a civil court procedure intended to aid persons with severe mental illness who require more intensive intervention to adhere to outpatient treatment to…
November 22, 2019
Introduction: Abrupt opioid withdrawal after chronic use results in central noradrenergic hyperactivity that is expressed clinically as opioid withdrawal syndrome (OWS). Patients with opioid use…
November 22, 2019
Background: The elevated prevalence of metabolic syndrome (MetS) in patients with depression has been associated with increased mortality rates. The aim of this post-hoc analysis was to assess the…
November 22, 2019
We assessed potential withdrawal symptoms in patients with treatment-resistant depression (TRD) after long-term, intermittent use of intranasal esketamine (ESK). Patients received ESK 2X/week and a…
November 22, 2019
Background: Tardive dyskinesia (TD) is a debilitating, often-irreversible hyperkinetic movement disorder that impairs patients’ abilities to perform daily activities. Deutetrabenazine was FDA-…
Back to Top